Format
Sort by

Send to

Choose Destination

Search results

Items: 14

1.

Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.

Chastek B, Korrer S, Nagar SP, Albers F, Yancey S, Ortega H, Forshag M, Dalal AA.

J Manag Care Spec Pharm. 2016 Jul;22(7):848-61. doi: 10.18553/jmcp.2016.22.7.848.

2.
3.

Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.

Curtis JR, Chastek B, Becker L, Quach C, Harrison DJ, Yun H, Joseph GJ, Collier DH.

J Manag Care Spec Pharm. 2015 Apr;21(4):318-29.

4.

Differences in survival for patients with metastatic colorectal cancer by lines of treatment received and stage at original diagnosis.

Seal B, Chastek B, Kulakodlu M, Valluri S.

Int J Clin Pract. 2015 Feb;69(2):251-8. doi: 10.1111/ijcp.12543.

PMID:
25302640
5.

Estimating the incidence and prevalence of juvenile-onset recurrent respiratory papillomatosis in publicly and privately insured claims databases in the United States.

Marsico M, Mehta V, Chastek B, Liaw KL, Derkay C.

Sex Transm Dis. 2014 May;41(5):300-5. doi: 10.1097/OLQ.0000000000000115.

6.

Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.

Chastek B, Kulakodlu M, Valluri S, Seal B.

Postgrad Med. 2013 Mar;125(2):73-82. doi: 10.3810/pgm.2013.03.2642.

PMID:
23816773
7.

Health care costs for patients with cancer at the end of life.

Chastek B, Harley C, Kallich J, Newcomer L, Paoli CJ, Teitelbaum AH.

J Oncol Pract. 2012 Nov;8(6):75s-80s. doi: 10.1200/JOP.2011.000469.

8.

Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data.

Curtis JR, Chastek B, Becker L, Harrison DJ, Collier D, Yun H, Joseph GJ.

Arthritis Res Ther. 2013 Mar 8;15(2):404. doi: 10.1186/ar4161. No abstract available.

9.

Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.

Chastek B, Fox KM, Watson C, Gandra SR.

Adv Ther. 2012 Aug;29(8):691-7. doi: 10.1007/s12325-012-0039-3.

PMID:
22903239
10.

Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population.

Chastek B, Fox KM, Watson C, Kricorian G, Gandra SR.

J Dermatolog Treat. 2013 Feb;24(1):25-33. doi: 10.3109/09546634.2012.661038.

PMID:
22668321
11.

Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population.

Amonkar MM, Chastek B, Samant N, Teitelbaum A.

J Med Econ. 2011;14(4):421-32. doi: 10.3111/13696998.2011.584096.

PMID:
21619455
12.

Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims.

Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV.

J Med Econ. 2010;13(4):618-25. doi: 10.3111/13696998.2010.523670.

PMID:
20883151
13.

Evaluation of hospitalization and follow-up care costs among patients hospitalized with ACS treated with a stent and clopidogrel.

Chastek B, Riedel AA, Wygant G, Hauch O.

Curr Med Res Opin. 2009 Dec;25(12):2845-52. doi: 10.1185/03007990903333017.

PMID:
19831706
14.

Health care costs among individuals with chronic obstructive pulmonary disease within several large, multi-state employers.

Darkow T, Chastek BJ, Shah H, Phillips AL.

J Occup Environ Med. 2008 Oct;50(10):1130-8. doi: 10.1097/JOM.0b013e31818837c8.

PMID:
18849758
Items per page

Supplemental Content

Loading ...
Support Center